# Hespecta Vaccination in HPV+ Tumors or Malignant Lesions

> **NCT02821494** · PHASE1 · COMPLETED · sponsor: **Leiden University** · enrollment: 25 (actual)

## Conditions studied

- Tumors or Premalignant Lesions

## Interventions

- **BIOLOGICAL:** Hespecta

## Key facts

- **NCT ID:** NCT02821494
- **Lead sponsor:** Leiden University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2020-03
- **Final completion:** 2020-03
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2021-02-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02821494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02821494, "Hespecta Vaccination in HPV+ Tumors or Malignant Lesions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02821494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*